SPC5004

**SPC5004** is an investigational low-dose, two-component antihypertensive combination developed by Shin Poong Pharmaceutical. It is being evaluated as one of the dual-component comparator therapies in a randomized Phase 2b trial of the related triple fixed-dose combination SPC1001 Low, which contains candesartan, amlodipine, and indapamide, in adults with essential hypertension. Public trial materials confirm SPC5004 as a study intervention but do not publicly specify which exact two components constitute SPC5004; therefore, no individual active ingredients or component-specific mechanisms are assigned here. ([ctv.veeva.com](https://ctv.veeva.com/study/evaluate-the-efficacy-and-safety-of-spc1001-low-in-patients-with-essential-hypertension))